Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Multiple Sclerosis

  Free Subscription


Articles published in J Neurol Sci

Retrieve available abstracts of 130 articles:
HTML format
Text format



Single Articles


    August 2019
  1. NOHARA S, Ishii A, Yamamoto F, Yanagiha K, et al
    GDF-15, a mitochondrial disease biomarker, is associated with the severity of multiple sclerosis.
    J Neurol Sci. 2019;405:116429.
    PubMed     Text format     Abstract available


  2. VANOLI E, Montano N, De Angelis G, Badilini F, et al
    Cardiovascular autonomic individual profile of relapsing-remitting multiple sclerosis patients and risk of extending cardiac monitoring after first dose fingolimod.
    J Neurol Sci. 2019;405:116423.
    PubMed     Text format     Abstract available


    July 2019
  3. BATCHELLER L, Baker D
    Cost of disease modifying therapies for multiple sclerosis: Is front-loading the answer?
    J Neurol Sci. 2019;404:19-28.
    PubMed     Text format     Abstract available


    June 2019
  4. MUCCILLI A, Nehme A, Labrie M, Girard M, et al
    Varicella-zoster virus vasculopathy in a multiple sclerosis patient on fingolimod.
    J Neurol Sci. 2019;403:119-121.
    PubMed     Text format    


  5. SEDEEQ MS, El-Nahrery EMA, Shalaby N, Hussein M, et al
    Micro-RNA-96 and interleukin-10 are independent biomarkers for multiple sclerosis activity.
    J Neurol Sci. 2019;403:92-96.
    PubMed     Text format     Abstract available


  6. MASUDA H, Mori M, Hirano S, Kojima K, et al
    Relapse numbers and earlier intervention by disease modifying drugs are related with progression of less brain atrophy in patients with multiple sclerosis.
    J Neurol Sci. 2019;403:78-84.
    PubMed     Text format     Abstract available


    May 2019
  7. DE ROQUEMAUREL A, Galli P, Landais A, Avendano S, et al
    Fingolimod for the treatment of multiple sclerosis in French West Indies, a real-world study in patients from African ancestry.
    J Neurol Sci. 2019;402:180-187.
    PubMed     Text format     Abstract available


    April 2019
  8. ZURAWSKI J, Glanz BI, Healy BC, Tauhid S, et al
    The impact of cervical spinal cord atrophy on quality of life in multiple sclerosis.
    J Neurol Sci. 2019;403:38-43.
    PubMed     Text format     Abstract available


    March 2019
  9. BOZIKI M, Lagoudaki R, Melo P, Kanidou F, et al
    Induction of apoptosis in CD4(+) T-cells is linked with optimal treatment response in patients with relapsing-remitting multiple sclerosis treated with Glatiramer acetate.
    J Neurol Sci. 2019;401:43-50.
    PubMed     Text format     Abstract available


  10. BEIER M, Hughes AJ, Williams MW, Gromisch ES, et al
    Brief and cost-effective tool for assessing verbal learning in multiple sclerosis: Comparison of the Rey Auditory Verbal Learning Test (RAVLT) to the California Verbal Learning Test - II (CVLT-II).
    J Neurol Sci. 2019;400:104-109.
    PubMed     Text format     Abstract available


    February 2019
  11. BEH SC
    The "eye of the tiger" in a patient with multiple sclerosis.
    J Neurol Sci. 2019;399:1-2.
    PubMed     Text format    


    January 2019
  12. FOX E, Vieira MC, Johnson K, Peeples M, et al
    Real-world durability of relapse rate reduction in patients with multiple sclerosis receiving fingolimod for up to 3years: a retrospective US claims database analysis.
    J Neurol Sci. 2019;398:163-170.
    PubMed     Text format     Abstract available


    December 2018
  13. ZACHARZEWSKA-GONDEK A, Pokryszko-Dragan A, Gondek TM, Koltowska A, et al
    Apparent diffusion coefficient measurements in normal appearing white matter may support the differential diagnosis between multiple sclerosis lesions and other white matter hyperintensities.
    J Neurol Sci. 2018;397:24-30.
    PubMed     Text format     Abstract available


    November 2018
  14. PENG A, Qiu X, Zhang L, Zhu X, et al
    Natalizumab exposure during pregnancy in multiple sclerosis: a systematic review.
    J Neurol Sci. 2018;396:202-205.
    PubMed     Text format    


  15. FRITZ NE, Kloos AD, Kegelmeyer DA, Kaur P, et al
    Supplementary motor area connectivity and dual-task walking variability in multiple sclerosis.
    J Neurol Sci. 2018;396:159-164.
    PubMed     Text format     Abstract available


  16. MEJIA M, Rodriguez-Leyva I, Cortes-Enriquez F, Chi-Ahumada E, et al
    Low levels of alpha-synuclein in peripheral tissues are related to clinical relapse in relapsing-remitting multiple sclerosis: a pilot cross-sectional study.
    J Neurol Sci. 2018;396:87-93.
    PubMed     Text format     Abstract available


    October 2018
  17. ZILIOTTO N, Zivadinov R, Jakimovski D, Baroni M, et al
    Plasma levels of soluble NCAM in multiple sclerosis.
    J Neurol Sci. 2018;396:36-41.
    PubMed     Text format     Abstract available


    September 2018
  18. HEALY BC, Glanz BI, Zurawski JD, Mazzola M, et al
    Long-term follow-up for multiple sclerosis patients initially treated with interferon-beta and glatiramer acetate.
    J Neurol Sci. 2018;394:127-131.
    PubMed     Text format     Abstract available


  19. POLACHINI CRN, Spanevello RM, Schetinger MRC, Morsch VM, et al
    Cholinergic and purinergic systems: A key to multiple sclerosis?
    J Neurol Sci. 2018;392:8-21.
    PubMed     Text format     Abstract available


    August 2018
  20. JAKIMOVSKI D, Weinstock-Guttman B, Hagemeier J, Vaughn CB, et al
    Walking disability measures in multiple sclerosis patients: Correlations with MRI-derived global and microstructural damage.
    J Neurol Sci. 2018;393:128-134.
    PubMed     Text format     Abstract available


  21. POKRYSZKO-DRAGAN A, Banaszek A, Nowakowska-Kotas M, Jezowska-Jurczyk K, et al
    Diffusion tensor imaging findings in the multiple sclerosis patients and their relationships to various aspects of disability.
    J Neurol Sci. 2018;391:127-133.
    PubMed     Text format     Abstract available


    July 2018
  22. CRISTIANO E, Rojas JI, Abad P, Adoni T, et al
    Consensus recommendations for the diagnosis and treatment of primary progressive multiple sclerosis in Latin America.
    J Neurol Sci. 2018;393:4-13.
    PubMed     Text format     Abstract available


  23. VOLLMER B, Honce JM, Sillau S, Corboy JR, et al
    The impact of very short transition times on switching from Natalizumab to Fingolimod on imaging and clinical effectiveness outcomes in multiple sclerosis.
    J Neurol Sci. 2018;390:89-93.
    PubMed     Text format     Abstract available


  24. ZHANG Y, Wang L, Jia H, Liao M, et al
    Genetic variants regulate NR1H3 expression and contribute to multiple sclerosis risk.
    J Neurol Sci. 2018;390:162-165.
    PubMed     Text format     Abstract available


    June 2018
  25. KHALID F, Healy BC, Dupuy SL, Chu R, et al
    Quantitative MRI analysis of cerebral lesions and atrophy in post-partum patients with multiple sclerosis.
    J Neurol Sci. 2018;392:94-99.
    PubMed     Text format     Abstract available


  26. GROMISCH ES, Portnoy JG, Foley FW
    Response to screening ability of cognitive function by two measures in patients with multiple sclerosis.
    J Neurol Sci. 2018 Jun 14. pii: S0022-510X(18)30259.
    PubMed     Text format    


  27. KAWADA T
    Screening ability of cognitive function by two measures in patients with multiple sclerosis.
    J Neurol Sci. 2018 Jun 13. pii: S0022-510X(18)30258.
    PubMed     Text format    


    May 2018
  28. KADRNOZKOVA L, Vaneckova M, Sobisek L, Benova B, et al
    Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year employment status in multiple sclerosis patients.
    J Neurol Sci. 2018;388:87-93.
    PubMed     Text format     Abstract available


  29. GROMISCH ES, Portnoy JG, Foley FW
    Comparison of the abbreviated minimal assessment of cognitive function in multiple sclerosis (aMACFIMS) and the brief international cognitive assessment for multiple sclerosis (BICAMS).
    J Neurol Sci. 2018;388:70-75.
    PubMed     Text format     Abstract available


  30. ZIVADINOV R, Bergsland N, Hagemeier J, Carl E, et al
    Effect of teriflunomide on gray and white matter brain pathology in multiple sclerosis using volumetric and diffusion-tensor imaging MRI measures.
    J Neurol Sci. 2018;388:175-181.
    PubMed     Text format     Abstract available


  31. KANTOR D, Johnson K, Vieira MC, Signorovitch J, et al
    Real-world persistence with fingolimod for the treatment of multiple sclerosis: A systematic review and meta-analysis.
    J Neurol Sci. 2018;388:168-174.
    PubMed     Text format     Abstract available


  32. FABIS-PEDRINI MJ, James I, Seewann A, Yau WY, et al
    Natural history of benign multiple sclerosis: Clinical and HLA correlates in a Western Australian cohort.
    J Neurol Sci. 2018;388:12-18.
    PubMed     Text format     Abstract available


  33. MANCA R, Sharrack B, Paling D, Wilkinson ID, et al
    Brain connectivity and cognitive processing speed in multiple sclerosis: A systematic review.
    J Neurol Sci. 2018;388:115-127.
    PubMed     Text format     Abstract available


    April 2018
  34. DALGAS U, Langeskov-Christensen M, Skjerbaek A, Jensen E, et al
    Is the impact of fatigue related to walking capacity and perceived ability in persons with multiple sclerosis? A multicenter study.
    J Neurol Sci. 2018;387:179-186.
    PubMed     Text format     Abstract available


  35. VYVER MV, Beelen R, De Keyser J, Nagels G, et al
    Plasma citrulline levels are increased in patients with multiple sclerosis.
    J Neurol Sci. 2018;387:174-178.
    PubMed     Text format     Abstract available


  36. ZIVADINOV R, Bergsland N, Hagemeier J, Tavazzi E, et al
    Effect of switching from glatiramer acetate 20mg/daily to glatiramer acetate 40mg three times a week on gray and white matter pathology in subjects with relapsing multiple sclerosis: A longitudinal DTI study.
    J Neurol Sci. 2018;387:152-156.
    PubMed     Text format     Abstract available


  37. AKAISHI T, Takahashi T, Nakashima I
    Oligoclonal bands and periventricular lesions in multiple sclerosis will not increase blood-brain barrier permeability.
    J Neurol Sci. 2018;387:129-133.
    PubMed     Text format     Abstract available


  38. GRIST JT, Riemer F, McLean MA, Matys T, et al
    Imaging intralesional heterogeneity of sodium concentration in multiple sclerosis: Initial evidence from (23)Na-MRI.
    J Neurol Sci. 2018;387:111-114.
    PubMed     Text format     Abstract available


    March 2018
  39. FENU G, Lorefice L, Arru M, Sechi V, et al
    Cognition in multiple sclerosis: Between cognitive reserve and brain volume.
    J Neurol Sci. 2018;386:19-22.
    PubMed     Text format     Abstract available


    February 2018
  40. MORROW SA, Rosehart H, Sener A, Welk B, et al
    Anti-cholinergic medications for bladder dysfunction worsen cognition in persons with multiple sclerosis.
    J Neurol Sci. 2018;385:39-44.
    PubMed     Text format     Abstract available


  41. BUNAI T, Terada T, Kono S, Yokokura M, et al
    Neuroinflammation following disease modifying therapy in multiple sclerosis: A pilot positron emission tomography study.
    J Neurol Sci. 2018;385:30-33.
    PubMed     Text format     Abstract available


  42. CRISTIANO E, Alonso R, Alvez Pinheiro A, Bacile EA, et al
    Argentinean recommendations on the identification of treatment failure in relapsing remitting multiple sclerosis patients.
    J Neurol Sci. 2018;385:217-224.
    PubMed     Text format     Abstract available


  43. PODBIELSKA M, O'Keeffe J, Hogan EL
    Autoimmunity in multiple sclerosis: role of sphingolipids, invariant NKT cells and other immune elements in control of inflammation and neurodegeneration.
    J Neurol Sci. 2018;385:198-214.
    PubMed     Text format     Abstract available


  44. CRISTIANO E, Alonso R, Alvez Pinheiro A, Bacile EA, et al
    Corrigendum to "Argentinean recommendations on the identification of treatment failure in relapsing remitting multiple sclerosis patients" [J. Neurol. Sci. 385C (2018) 217-224].
    J Neurol Sci. 2018 Feb 12. pii: S0022-510X(18)30061.
    PubMed     Text format    


    January 2018
  45. BERTSCH-GOUT M, Loeb R, Finch AK, Javed A, et al
    High resolution retinal scanning reveals regional structural differences between MS and NMOSD optic neuritis regardless of antibody status.
    J Neurol Sci. 2018;384:61-66.
    PubMed     Text format     Abstract available


    December 2017
  46. DALLA-COSTA G, Radaelli M, Maida S, Sangalli F, et al
    Smart watch, smarter EDSS: Improving disability assessment in multiple sclerosis clinical practice.
    J Neurol Sci. 2017;383:166-168.
    PubMed     Text format     Abstract available


  47. LINGENBERG A, Laidet M, Armand S, Herrmann FR, et al
    Gait stability in patients treated by fingolimod: A longitudinal pilot study on 9 patients with multiple sclerosis.
    J Neurol Sci. 2017;383:105-107.
    PubMed     Text format    


    November 2017
  48. PEREZ-MARTIN MY, Gonzalez-Platas M, Jimenez-Sosa A, Plata-Bello J, et al
    Can fibrinolytic system components explain cognitive impairment in multiple sclerosis?
    J Neurol Sci. 2017;382:66-72.
    PubMed     Text format     Abstract available


  49. PLANCHE V, Moisset X, Morello R, Dumont E, et al
    Improvement of quality of life and its relationship with neuropsychiatric outcomes in patients with multiple sclerosis starting treatment with natalizumab: A 3-year follow-up multicentric study.
    J Neurol Sci. 2017;382:148-154.
    PubMed     Text format     Abstract available


  50. LANGESKOV-CHRISTENSEN D, Feys P, Baert I, Riemenschneider M, et al
    Performed and perceived walking ability in relation to the Expanded Disability Status Scale in persons with multiple sclerosis.
    J Neurol Sci. 2017;382:131-136.
    PubMed     Text format     Abstract available


    October 2017
  51. YOUSUF F, Dupuy SL, Tauhid S, Chu R, et al
    A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis.
    J Neurol Sci. 2017 Oct 16. pii: S0022-510X(17)34384.
    PubMed     Text format     Abstract available


  52. MILLER P, Soundy A
    The pharmacological and non-pharmacological interventions for the management of fatigue related multiple sclerosis.
    J Neurol Sci. 2017;381:41-54.
    PubMed     Text format     Abstract available


  53. KARAMI M, Mehrabi F, Allameh A, Pahlevan Kakhki M, et al
    Klotho gene expression decreases in peripheral blood mononuclear cells (PBMCs) of patients with relapsing-remitting multiple sclerosis.
    J Neurol Sci. 2017;381:305-307.
    PubMed     Text format     Abstract available


  54. FERREIRA D, Castro P, Videira G, Filipe JP, et al
    Cerebral autoregulation is preserved in multiple sclerosis patients.
    J Neurol Sci. 2017;381:298-304.
    PubMed     Text format     Abstract available


  55. CALVI A, De Riz M, Lecchi E, Pietroboni A, et al
    Merkel cell carcinoma in a patient with relapsing-remitting multiple sclerosis treated with fingolimod.
    J Neurol Sci. 2017;381:296-297.
    PubMed     Text format    


  56. OLIVEIRA SR, Simao ANC, Alfieri DF, Flauzino T, et al
    Vitamin D deficiency is associated with disability and disease progression in multiple sclerosis patients independently of oxidative and nitrosative stress.
    J Neurol Sci. 2017;381:213-219.
    PubMed     Text format     Abstract available


  57. CORREALE J
    Follow-on products for treatment of multiple sclerosis in Latin America: An update.
    J Neurol Sci. 2017;381:153-159.
    PubMed     Text format     Abstract available


  58. BEIER M, Gromisch ES, Hughes AJ, Alschuler KN, et al
    Proposed cut scores for tests of the Brief International Cognitive Assessment of Multiple Sclerosis (BICAMS).
    J Neurol Sci. 2017;381:110-116.
    PubMed     Text format     Abstract available


  59. MCGEE JC, Minagar A
    Assessing the cerebral gray matter volume in response to fingolimod therapy in multiple sclerosis: A more analytic view.
    J Neurol Sci. 2017 Oct 13. pii: S0022-510X(17)34383.
    PubMed     Text format    


    September 2017
  60. YAMOUT BI, Said M, Hannoun S, Zeineddine M, et al
    Rebound syndrome after teriflunomide cessation in a patient with multiple sclerosis.
    J Neurol Sci. 2017;380:79-81.
    PubMed     Text format     Abstract available


  61. YANG TT, Wang L, Deng XY, Yu G, et al
    Pharmacological treatments for fatigue in patients with multiple sclerosis: A systematic review and meta-analysis.
    J Neurol Sci. 2017;380:256-261.
    PubMed     Text format     Abstract available


  62. GREEKE EE, Chua AS, Healy BC, Rintell DJ, et al
    Depression and fatigue in patients with multiple sclerosis.
    J Neurol Sci. 2017;380:236-241.
    PubMed     Text format     Abstract available


  63. IWANOWSKI P, Losy J, Kramer L, Wojcicka M, et al
    CXCL10 and CXCL13 chemokines in patients with relapsing remitting and primary progressive multiple sclerosis.
    J Neurol Sci. 2017;380:22-26.
    PubMed     Text format     Abstract available


  64. LAIDET M, Herrmann FR, Armand S, Assal F, et al
    Does fear of falling predict gait variability in multiple sclerosis?
    J Neurol Sci. 2017;380:212-214.
    PubMed     Text format     Abstract available


  65. SCARPAZZA C, Prosperini L, Mancinelli CR, De Rossi N, et al
    Corrigendum to "Is maraviroc useful in multiple sclerosis patients with natalizumab-related progressive multifocal leukoencephalopathy?" [J. Neurol. Sci. 378 (2017) 233-237].
    J Neurol Sci. 2017;380:19.
    PubMed     Text format    


  66. PICELLI A, Vallies G, Chemello E, Castellazzi P, et al
    Is spasticity always the same? An observational study comparing the features of spastic equinus foot in patients with chronic stroke and multiple sclerosis.
    J Neurol Sci. 2017;380:132-136.
    PubMed     Text format     Abstract available


    August 2017
  67. SANTORO M, Mirabella M, De Fino C, Bianco A, et al
    Sativex(R) effects on promoter methylation and on CNR1/CNR2 expression in peripheral blood mononuclear cells of progressive multiple sclerosis patients.
    J Neurol Sci. 2017;379:298-303.
    PubMed     Text format     Abstract available


  68. GAETANI L, Fanelli F, Riccucci I, Eusebi P, et al
    High risk of early conversion to multiple sclerosis in clinically isolated syndromes with dissemination in space at baseline.
    J Neurol Sci. 2017;379:236-240.
    PubMed     Text format     Abstract available


  69. KEUNE PM, Young WR, Paraskevopoulos IT, Hansen S, et al
    Measuring standing balance in multiple sclerosis: Further progress towards an automatic and reliable method in clinical practice.
    J Neurol Sci. 2017;379:157-162.
    PubMed     Text format     Abstract available


  70. MORSALJAHAN Z, Rafiei A, Valadan R, Abedini M, et al
    Association between interleukin-32 polymorphism and multiple sclerosis.
    J Neurol Sci. 2017;379:144-150.
    PubMed     Text format     Abstract available


    July 2017
  71. FARROKHI M, Masoudifar A, Peykanpour F
    Interleukin 17 and 10 in relapsing remitting multiple sclerosis.
    J Neurol Sci. 2017;378:63.
    PubMed     Text format    


  72. ROLF L, Muris AH, Bol Y, Damoiseaux J, et al
    Vitamin D3 supplementation in multiple sclerosis: Symptoms and biomarkers of depression.
    J Neurol Sci. 2017;378:30-35.
    PubMed     Text format     Abstract available


  73. SCARPAZZA C, Prosperini L, Mancinelli CR, De Rossi N, et al
    Is maraviroc useful in multiple sclerosis patients with natalizumab-related progressive multifocal leukoencephalopathy?
    J Neurol Sci. 2017;378:233-237.
    PubMed     Text format     Abstract available


  74. TAWFIK TZ, Gad AH, Mehaney DA, El Nahrery E, et al
    Concerning the article "Interleukins 17 and 10 in a sample of Egyptian relapsing remitting multiple sclerosis patients".
    J Neurol Sci. 2017;378:152.
    PubMed     Text format    


    June 2017
  75. AGLIARDI C, Guerini FR, Zanzottera M, Rovaris M, et al
    Indoleamine-2,3-dioxygenase(IDO)2 polymorphisms are not associated with multiple sclerosis in Italians.
    J Neurol Sci. 2017;377:31-34.
    PubMed     Text format     Abstract available


  76. CALABRO RS, Russo M, Naro A, De Luca R, et al
    Robotic gait training in multiple sclerosis rehabilitation: Can virtual reality make the difference? Findings from a randomized controlled trial.
    J Neurol Sci. 2017;377:25-30.
    PubMed     Text format     Abstract available


  77. TRENTINI A, Castellazzi M, Romani A, Squerzanti M, et al
    Evaluation of total, ceruloplasmin-associated and type II ferroxidase activities in serum and cerebrospinal fluid of multiple sclerosis patients.
    J Neurol Sci. 2017;377:133-136.
    PubMed     Text format     Abstract available


  78. SMOLDERS J, Rolf L, Damoiseaux J, Hupperts R, et al
    On the ethics of not supplementing low 25-hydroxyvitamin D levels in a controlled study in relapsing remitting multiple sclerosis.
    J Neurol Sci. 2017 Jun 9. pii: S0022-510X(17)30383.
    PubMed     Text format    


  79. SHUKLA L, Solanki C, Kulkarni Y, Vadlamani N, et al
    Vitamin D supplementation; effects on depressive symptoms in multiple sclerosis.
    J Neurol Sci. 2017 Jun 9. pii: S0022-510X(17)30384.
    PubMed     Text format    


    May 2017
  80. JORGENSEN M, Dalgas U, Wens I, Hvid LG, et al
    Muscle strength and power in persons with multiple sclerosis - A systematic review and meta-analysis.
    J Neurol Sci. 2017;376:225-241.
    PubMed     Text format     Abstract available


  81. HEESEN C, Kleiter I, Meuth SG, Kramer J, et al
    Benefit-risk perception of natalizumab therapy in neurologists and a large cohort of multiple sclerosis patients.
    J Neurol Sci. 2017;376:181-190.
    PubMed     Text format     Abstract available


  82. BSTEH G, Monz E, Zamarian L, Hagspiel S, et al
    Combined evaluation of personality, risk and coping in MS patients: A step towards individualized treatment choice - The PeRiCoMS-Study I.
    J Neurol Sci. 2017;376:71-75.
    PubMed     Text format     Abstract available


  83. WEINSTOCK-GUTTMAN B, Nair KV, Glajch JL, Ganguly TC, et al
    Two decades of glatiramer acetate: From initial discovery to the current development of generics.
    J Neurol Sci. 2017;376:255-259.
    PubMed     Text format     Abstract available


    April 2017
  84. BOURNE T, Waltz M, Casper TC, Kavak K, et al
    Evaluating the association of allergies with multiple sclerosis susceptibility risk and disease activity in a pediatric population.
    J Neurol Sci. 2017;375:371-375.
    PubMed     Text format     Abstract available


  85. LYSANDROPOULOS AP, Mavroudakis N, Pandolfo M, El Hafsi K, et al
    HLA genotype as a marker of multiple sclerosis prognosis: A pilot study.
    J Neurol Sci. 2017;375:348-354.
    PubMed     Text format     Abstract available


  86. NOORI-ZADEH A, Mesbah-Namin SA, Saboor-Yaraghi AA
    Epigenetic and gene expression alterations of FOXP3 in the T cells of EAE mouse model of multiple sclerosis.
    J Neurol Sci. 2017;375:203-208.
    PubMed     Text format     Abstract available


  87. RUBEGNI A, Battisti C, Tessa A, Cerase A, et al
    SPG2 mimicking multiple sclerosis in a family identified using next generation sequencing.
    J Neurol Sci. 2017;375:198-202.
    PubMed     Text format     Abstract available


  88. HARTL C, Obermeier V, Gerdes LA, Brugel M, et al
    Seasonal variations of 25-OH vitamin D serum levels are associated with clinical disease activity in multiple sclerosis patients.
    J Neurol Sci. 2017;375:160-164.
    PubMed     Text format     Abstract available


  89. REEN GK, Silber E, Langdon DW
    Multiple sclerosis patients' understanding and preferences for risks and benefits of disease-modifying drugs: A systematic review.
    J Neurol Sci. 2017;375:107-122.
    PubMed     Text format     Abstract available


    February 2017
  90. ZHOU Y, Fang L, Peng L, Qiu W, et al
    TLR9 and its signaling pathway in multiple sclerosis.
    J Neurol Sci. 2017;373:95-99.
    PubMed     Text format     Abstract available


  91. WUNDES A, Bowen JD, Kraft GH, Maravilla KR, et al
    Brain pathology of a patient 7years after autologous hematopoietic stem cell transplantation for multiple sclerosis.
    J Neurol Sci. 2017;373:339-341.
    PubMed     Text format     Abstract available


  92. LANGESKOV-CHRISTENSEN M, Bisson EJ, Finlayson ML, Dalgas U, et al
    Potential pathophysiological pathways that can explain the positive effects of exercise on fatigue in multiple sclerosis: A scoping review.
    J Neurol Sci. 2017;373:307-320.
    PubMed     Text format     Abstract available


  93. FERREIRA KP, Oliveira SR, Kallaur AP, Kaimen-Maciel DR, et al
    Disease progression and oxidative stress are associated with higher serum ferritin levels in patients with multiple sclerosis.
    J Neurol Sci. 2017;373:236-241.
    PubMed     Text format     Abstract available


  94. KAWADA T
    Poor sleep and fatigue in patients with multiple sclerosis.
    J Neurol Sci. 2017;373:143.
    PubMed     Text format    


  95. NOCITI V, Losavio FA, Gnoni V, Losurdo A, et al
    Response to the letter to the Editor for the manuscript "Sleep and Fatigue in Multiple Sclerosis: A questionnaire-based, cross-sectional, cohort study" by Tomoyuki Kawada.
    J Neurol Sci. 2017;373:142.
    PubMed     Text format    


  96. ZAHOOR I, Haq E, Asimi R
    Multiple sclerosis in Kashmir: Where we stand.
    J Neurol Sci. 2017;373:129-133.
    PubMed     Text format     Abstract available


  97. TOGHI M, Taheri M, Arsang-Jang S, Ohadi M, et al
    SOCS gene family expression profile in the blood of multiple sclerosis patients.
    J Neurol Sci. 2017 Feb 9. pii: S0022-510X(17)30111.
    PubMed     Text format     Abstract available


    January 2017
  98. ALGAHTANI H, Marzouk Y, Algahtani R, Salman S, et al
    Autosomal Recessive Cerebellar Ataxia type 1 mimicking multiple sclerosis: A report of two siblings with a novel mutation in SYNE1 gene in a Saudi family.
    J Neurol Sci. 2017;372:97-100.
    PubMed     Text format     Abstract available


  99. MOTL RW, Sandroff BM, Pilutti LA, Klaren RE, et al
    Physical activity, sedentary behavior, and aerobic capacity in persons with multiple sclerosis.
    J Neurol Sci. 2017;372:342-346.
    PubMed     Text format     Abstract available


  100. BOESCHOTEN RE, Braamse AM, Beekman AT, Cuijpers P, et al
    Prevalence of depression and anxiety in Multiple Sclerosis: A systematic review and meta-analysis.
    J Neurol Sci. 2017;372:331-341.
    PubMed     Text format     Abstract available


  101. CAMEROTA F, Celletti C, Di Sipio E, De Fino C, et al
    Focal muscle vibration, an effective rehabilitative approach in severe gait impairment due to multiple sclerosis.
    J Neurol Sci. 2017;372:33-39.
    PubMed     Text format     Abstract available


  102. SABATINO JJ JR, Newsome SD
    Stiff person syndrome masquerading as multiple sclerosis.
    J Neurol Sci. 2017;372:297-299.
    PubMed     Text format     Abstract available


  103. CRNOSIJA L, Krbot Skoric M, Gabelic T, Adamec I, et al
    Vestibular evoked myogenic potentials and MRI in early multiple sclerosis: Validation of the VEMP score.
    J Neurol Sci. 2017;372:28-32.
    PubMed     Text format     Abstract available


  104. KISIC-TEPAVCEVIC D, Pekmezovic T, Trajkovic G, Stojsavljevic N, et al
    Corrigendum to "Sexual dysfunction in multiple sclerosis: A 6-year follow-up study" [J. Neurol. Sci. 358 (2015) 317-323].
    J Neurol Sci. 2017;372:201.
    PubMed     Text format    


  105. CHALAH MA, Riachi N, Ahdab R, Mhalla A, et al
    Effects of left DLPFC versus right PPC tDCS on multiple sclerosis fatigue.
    J Neurol Sci. 2017;372:131-137.
    PubMed     Text format     Abstract available


  106. TAO C, Simpson S Jr, Taylor BV, van der Mei I, et al
    Association between human herpesvirus & human endogenous retrovirus and MS onset & progression.
    J Neurol Sci. 2017;372:239-249.
    PubMed     Text format     Abstract available


  107. BEH SC, Kildebeck E, Narayan R, Desena A, et al
    High-dose methotrexate with leucovorin rescue: For monumentally severe CNS inflammatory syndromes.
    J Neurol Sci. 2017;372:187-195.
    PubMed     Text format     Abstract available


  108. TANIKAWA M, Nakahara J, Hata J, Suzuki S, et al
    q-Space Myelin Map imaging for longitudinal analysis of demyelination and remyelination in multiple sclerosis patients treated with fingolimod: A preliminary study.
    J Neurol Sci. 2017 Jan 5. pii: S0022-510X(17)30010.
    PubMed     Text format     Abstract available


  109. KIRA JI
    q-space Myelin Map imaging: A new imaging technique for treatment evaluation in multiple sclerosis.
    J Neurol Sci. 2017 Jan 4. pii: S0022-510X(17)30009.
    PubMed     Text format    


    December 2016
  110. KOUDRIAVTSEVA T
    Body mass index and interferon-beta efficacy (and safety) in multiple sclerosis.
    J Neurol Sci. 2016;371:79-80.
    PubMed     Text format    


    November 2016
  111. HERNANDEZ ME, Holtzer R, Chaparro G, Jean K, et al
    Brain activation changes during locomotion in middle-aged to older adults with multiple sclerosis.
    J Neurol Sci. 2016;370:277-283.
    PubMed     Text format     Abstract available


  112. SQUINTANI G, Donato F, Turri M, Deotto L, et al
    Cortical and spinal excitability in patients with multiple sclerosis and spasticity after oromucosal cannabinoid spray.
    J Neurol Sci. 2016;370:263-268.
    PubMed     Text format     Abstract available


  113. O'GORMAN CM, Broadley SA
    Smoking increases the risk of progression in multiple sclerosis: A cohort study in Queensland, Australia.
    J Neurol Sci. 2016;370:219-223.
    PubMed     Text format     Abstract available


  114. DE GIGLIO L, Upadhyay N, De Luca F, Prosperini L, et al
    Corpus callosum microstructural changes associated with Kawashima Nintendo Brain Training in patients with multiple sclerosis.
    J Neurol Sci. 2016;370:211-213.
    PubMed     Text format    


  115. GAINDH D, Kavak KS, Teter B, Vaughn CB, et al
    Decreased risk of cancer in multiple sclerosis patients and analysis of the effect of disease modifying therapies on cancer risk.
    J Neurol Sci. 2016;370:13-17.
    PubMed     Text format     Abstract available


  116. GASPERINI C, Hupperts R, Lycke J, Short C, et al
    Prolonged-release fampridine treatment improved subject-reported impact of multiple sclerosis: Item-level analysis of the MSIS-29.
    J Neurol Sci. 2016;370:123-131.
    PubMed     Text format     Abstract available


  117. HUHN K, Lammer R, Zimmermann H, Lammer A, et al
    Retinal imaging and axonal degeneration in later onset multiple sclerosis.
    J Neurol Sci. 2016;370:1-6.
    PubMed     Text format     Abstract available


    October 2016
  118. NOCITI V, Losavio FA, Gnoni V, Losurdo A, et al
    Sleep and fatigue in multiple sclerosis: A questionnaire-based, cross-sectional, cohort study.
    J Neurol Sci. 2016 Oct 27. pii: S0022-510X(16)30684.
    PubMed     Text format     Abstract available


  119. EFTEKHARIAN MM, Noroozi R, Sayad A, Sarrafzadeh S, et al
    RAR-related orphan receptor A (RORA): A new susceptibility gene for multiple sclerosis.
    J Neurol Sci. 2016;369:259-62.
    PubMed     Text format     Abstract available


  120. BERNARDINI LR, Zecca C, Clerici VT, Gobbi C, et al
    Severe articular and musculoskeletal pain: An unexpected side effect of dimethyl-fumarate therapy for multiple sclerosis.
    J Neurol Sci. 2016;369:139-40.
    PubMed     Text format    


  121. YANG F, Estrada EF, Sanchez MC
    Vibration training improves disability status in multiple sclerosis: A pretest-posttest pilot study.
    J Neurol Sci. 2016;369:96-101.
    PubMed     Text format     Abstract available


  122. MANDEL JJ, Goethe EA, Patel AJ, Heck K, et al
    Newly diagnosed ganglioglioma in an adult patient with multiple sclerosis.
    J Neurol Sci. 2016;369:51-2.
    PubMed     Text format    


  123. TAWFIK TZ, Gad AH, Mehaney DA, El Nahrery E, et al
    Interleukins 17 and 10 in a sample of Egyptian relapsing remitting multiple sclerosis patients.
    J Neurol Sci. 2016;369:36-8.
    PubMed     Text format     Abstract available


    September 2016
  124. BRAMBILLA L, Rossi Sebastiano D, Aquino D, Torri Clerici V, et al
    Early effect of dalfampridine in patients with MS: A multi-instrumental approach to better investigate responsiveness.
    J Neurol Sci. 2016;368:402-7.
    PubMed     Text format     Abstract available


  125. MESSMER UCCELLI M, Traversa S, Ponzio M
    A survey study comparing young adults with MS and healthy controls on self-esteem, self-efficacy, mood and quality of life.
    J Neurol Sci. 2016;368:369-73.
    PubMed     Text format     Abstract available


  126. SACCA F, Pane C, Carotenuto A, Massarelli M, et al
    The use of medical-grade cannabis in patients non-responders to Nabiximols.
    J Neurol Sci. 2016;368:349-51.
    PubMed     Text format    


    June 2016
  127. KUUSISTO H, Vahvelainen T, Hamalainen P, Luukkaala T, et al
    Asymptomatic subjects differ less from their twin siblings with MS than from healthy controls in cognitive functioning. A Finnish Twin Cohort study.
    J Neurol Sci. 2016;365:50-3.
    PubMed     Text format     Abstract available


    April 2016
  128. TREMLETT H, Fadrosh DW, Faruqi AA, Hart J, et al
    Gut microbiota composition and relapse risk in pediatric MS: A pilot study.
    J Neurol Sci. 2016;363:153-7.
    PubMed     Text format     Abstract available


    March 2016
  129. HUDA S, Cavey A, Izat A, Mattison P, et al
    Nurse led telephone assessment of expanded disability status scale assessment in MS patients at high levels of disability.
    J Neurol Sci. 2016;362:66-8.
    PubMed     Text format     Abstract available


    January 2016
  130. MOORE P, Methley A, Pollard C, Mutch K, et al
    Cognitive and psychiatric comorbidities in neuromyelitis optica.
    J Neurol Sci. 2016;360:4-9.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: